With One in Four Adults Overweight, Are Weight-Loss Drugs Sparking India’s Fight Against Obesity?

With one in four Indian adults now classified as overweight, the country faces a growing public health crisis — and a potential turning point.

The rise of new-generation weight-loss drugs, once accessible only in the West, is beginning to reshape India’s approach to obesity and metabolic health.

According to recent health data, obesity rates have nearly doubled in urban India over the past two decades, driven by sedentary lifestyles, processed food consumption, and stress-related eating. Doctors warn that the condition is no longer limited to affluent populations — it’s now widespread across age groups and regions, contributing to soaring rates of diabetes, hypertension, and heart disease.

Enter a new wave of prescription medications such as semaglutide and liraglutide — GLP-1 receptor agonists originally developed to manage diabetes but now proven to aid significant weight loss. These drugs, popularized globally under brand names like Ozempic and Wegovy, are beginning to make their way into India’s pharmaceutical market, sparking both hope and debate.

Health experts believe these medications could offer a much-needed solution for patients struggling with obesity-related complications. “For many, lifestyle modification alone doesn’t lead to sustainable results. These drugs can be life-changing when used responsibly,” says Dr. Ramesh Bhattacharya, an endocrinologist based in Delhi.

However, the excitement is tempered by concerns about accessibility, affordability, and misuse. A month’s supply can cost anywhere from ₹15,000 to ₹25,000, making it unaffordable for most Indians. Moreover, medical professionals caution that the drugs should only be used under supervision, as sudden withdrawal or incorrect dosing can lead to adverse effects.

Despite challenges, India’s health ecosystem is witnessing a cultural shift — where obesity is increasingly seen not as a failure of willpower, but as a chronic, treatable condition. With pharmaceutical advances, greater awareness, and evolving medical guidelines, the country could be on the cusp of a new era in its battle against obesity — one driven as much by science as by self-acceptance.